Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.

As more drugs go subcutaneous, Phillips Medisize's director of Front-End Innovation, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

TxSphere designed its technology to deliver drugs at a higher volume and higher viscosity than traditional autoinjectors.

In an unlikely collaboration between Skoltech's Petroleum Center and the drug delivery team from the Institute's Neuro Center ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on ...

In a study published in the Journal of Extracellular Vesicles, scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a ...